• Home
  • Search Results

Search Results

Open
Cancer
181 studies match your search
Open

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Have you been diagnosed with advanced unresectable pancreatic cancer. If so, you may be able to take part in a research study looking at the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Open

A phase II trial of induction and maintenance pembrolizumab and olaparib in locally advanced head and neck squamous cell carcinoma (HNSCC)

Have you been diagnosed with locally advanced head and neck squamous cell carcinoma? If so, you may be able to participate in a research study to evaluate whether pembrolizumab and olaparib given before and after chemoradiotherapy can improve 1-year progression free survival.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Head and Neck)
Open

Impact of the Uterine and Gut Microbiomes in Endometrial Cancer Development and Treatment

Do you have a newly diagnosed endometrial cancer? if so, you may be eligible to participate in a research study looking at the role the uterine and gut microbiomes play in endometrial cancer development and treatment.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
  • Microbiome
  • Women's Health
Open

Linvolseltamab Plus Other Cancer Treatments for Relapsed/Refractory Multiple Myeloma

Have you been diagnosed with multiple myeloma that has returned and needed to be treated again? If so, you may be able to take part in a research study looking at the safety of giving a new drug called REGN5458 (Linvoseltamab) to patients with relapsed/refractory multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Phase 1 Trials (all cancers), Multiple Myeloma)
Open

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Do you have non-small-cell lung cancer? Did your cancer get worse after, or while you were on treatment? If so, you may be eligible to participate in a research study that uses your own modified immune cells as possible treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
Open

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Have you been recently diagnosed with Diffuse Large B Cell Lymphoma? Are you over 75 years of age? If so, you may be able to take part in a research study looking at the safety of giving a new study drug CC-486 (oral azacitidine) in addition to the standard chemotherapy drug combination used to treat this disease.

Age & Gender
  • 75 years ~ 99 years
  • Male, Female
Study Interest
  • Aging
  • Cancer (Lymphoma)
Open

CAR-T cells targeting the kappa antigen for Relapsed/ Refractory mantle cell and indolent non-Hodgkin lymphomas

Do you have mantle cell lymphoma or other non-Hodgkin lymphoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lymphoma)
Open

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

UNC Multidisciplinary Melanoma and Uncommon Skin Lesion Registry

Do you want to help us learn more about skin cancers with little effort on your part? We would like to collect data from your medical record and use tissues sitting in storage to help us better understand how skin cancers work and find treatments/cures. Contact us today to find out how you can be a part of ground-breaking research!

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Melanoma, Other Cancers)
  • Skin, Hair, and Nails
  • Surgery and post-operative healing
Visit Location
100% Remote (online, phone, text)
Open

Measuring cancer cells in the blood of head and neck cancer patients receiving surgery

Will you be treated for Locally Advanced Head and Neck Squamous Cell Carcinoma? Have you been cancer free for at least two years after previous treatment? If so, you may eligible to participate in a clinical research trial aimed to measure the level of ctDNA in the blood before and after treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Blood Conditions
  • Cancer (Head and Neck)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research